Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Published ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

The upcoming interim Phase 1 data, expected in December, has generated optimism due to management’s confidence and the drug’s potential to outperform existing treatments like Dupixent. This optimism ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

Regeneron Pharmaceuticals Inc. (REGN)股价已触及52周低点，交易价格为785.31美元。这一价格水平反映出过去一年来股价出现了0.43%的微小但显著下跌，表明这家以创新药物闻名的生物技术公司正处于整固期。投资者正密切关注该股在这一低点的表现，考虑公司的业绩以及可能影响未来几个月走势的潜在市场动向。 在其他近期新闻中，Regeneron Pharmaceutica ...

The brand spent an estimated $18.1 million on national TV advertising, receiving the greatest ROI from CBS and its daytime ...